IHH Healthcare Berhad (KLSE:IHH) Half-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

The half-yearly results for IHH Healthcare Berhad (KLSE:IHH) were released last week, making it a good time to revisit its performance. Results were roughly in line with estimates, with revenues of RM14b and statutory earnings per share of RM0.065. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on IHH Healthcare Berhad after the latest results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the consensus forecast from IHH Healthcare Berhad's 23 analysts is for revenues of RM28.5b in 2026. This reflects a modest 6.6% improvement in revenue compared to the last 12 months. Statutory per-share earnings are expected to be RM0.26, roughly flat on the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of RM28.3b and earnings per share (EPS) of RM0.26 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

See our latest analysis for IHH Healthcare Berhad

There were no changes to revenue or earnings estimates or the price target of RM10.18, suggesting that the company has met expectations in its recent result. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values IHH Healthcare Berhad at RM11.43 per share, while the most bearish prices it at RM8.50. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting IHH Healthcare Berhad's growth to accelerate, with the forecast 14% annualised growth to the end of 2026 ranking favourably alongside historical growth of 11% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 11% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect IHH Healthcare Berhad to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at RM10.18, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for IHH Healthcare Berhad going out to 2028, and you can see them free on our platform here.

You still need to take note of risks, for example - IHH Healthcare Berhad has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.